Nephrogenic system fibrosis: A radiologist's practical perspective

European Journal of Radiology

Volumn 66, Issue 2, 2008, Pages 220-224

  Martin, Diego R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CIN; Contrast induced nephropathy; CT; Dialysis; Gadolinium; Gadolinium based contrast agents; Gadolinium chelates; Informed consent; Iodinated contrast; Kidney; Magnetic resonance imaging; MRI; Nephrogenic systemic fibrosis; NSF; Renal

Indexed keywords

BIOLOGICAL ORGANS; CHELATION; DIALYSIS; MAGNETIC RESONANCE IMAGING;

CONTRAST INDUCED NEPHROPATHY; GADOLINIUM BASED CONTRAST AGENTS; GADOLINIUM-CHELATES; NEPHROGENIC SYSTEMIC FIBROSIS;

GADOLINIUM;

ACETYLSALICYLIC ACID; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IODINATED CONTRAST MEDIUM;

ARTICLE; CONTRAST ENHANCEMENT; DOSE RESPONSE; DRUG CLEARANCE; DRUG EXCRETION; DRUG MEGADOSE; HUMAN; INFORMED CONSENT; KIDNEY DISEASE; KIDNEY FUNCTION; NEPHROGENIC FIBROSING DERMOPATHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOLOGIST; RENAL REPLACEMENT THERAPY; RISK FACTOR;

CONTRAST MEDIA; DOCUMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; GADOLINIUM; HUMANS; INFORMED CONSENT; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; RENAL DIALYSIS; RISK FACTORS; SKIN DISEASES;

EID: 43049130289     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.01.029     Document Type: Article

References (34)

1. U.S. Food and Drug Administration. FDA news: FDA requests boxed warning for contrast agents used to improve MRI images. Food and Drug Administration Web site. http://wwwfdagov/bbs/topics/NEWS/2007/NEW01638html Published May 23, 2007. Accessed June 19, 2007.
2. Cowper S.E., Su L.D., Bhawan J., Robin H.S., and LeBoit P.E. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23 (2001) 383-393
3. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant (2006)
4. Marckmann P., Skov L., Rossen K., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 (2006) 2359-2362
5. Thomsen H.S. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 16 (2006) 2619-2621
6. Thomsen H.S., Morcos S.K., and Dawson P. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?. Clin Radiol 61 (2006) 905-906
7. Peak A.S., and Sheller A. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis. Ann Pharmacother 41 (2007) 1481-1485
8. Grobner T., and Prischl F.C. Gadolinium and nephrogenic systemic fibrosis. Kidney Int 72 (2007) 260-264
9. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 (2007) 148-157
10. Lauenstein T.C., Salman K., Morreira R., et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging 26 (2007) 1198-1203
11. Deo A., Fogel M., and Cowper S.E. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2 (2007) 264-267
12. Broome D.R., Girguis M.S., Baron P.W., Cottrell A.C., Kjellin I., and Kirk G.A. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 188 (2007) 586-592
13. Cowper S.E., and Boyer P.J. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 8 (2006) 151-157
14. Herget-Rosenthal S., Bokenkamp A., and Hofmann W. How to estimate GFR-serum creatinine, serum cystatin C or equations?. Clin Biochem 40 (2007) 153-161
15. Giersig C. [Nephrogenic systemic fibrosis as an adverse drug reaction of gadolinium-based contrast media for magnetic resonance imaging]. Radiology (2007)
16. Thomsen H.S., Marckmann P., and Logager V.B. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 7 (2007) 130-137
17. Lin S.P., and Brown J.J. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging 25 (2007) 884-899
18. High W.A., Ayers R.A., and Cowper S.E. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 (2007) 710-712
19. High W.A., Ayers R.A., Chandler J., Zito G., and Cowper S.E. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 (2007) 21-26
20. Thomsen H.S., and Morcos S.K. Nephrogenic systemic fibrosis and nonionic linear chelates. AJR Am J Roentgenol 188 (2007) W580 author reply W581
21. Marckmann P., Skov L., Rossen K., Heaf J.G., and Thomsen H.S. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant (2007)
22. Saab G., and Abu-Alfa A. Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?. AJR Am J Roentgenol 189 (2007) W169
23. Clorius S., Technau K., Watter T., et al. Nephrogenic systemic fibrosis following exposure to gadolinium-containing contrast agent. Clin Nephrol 68 (2007) 249-252
24. Lee C.I., Flaster H.V., Haims A.H., Monico E.P., and Forman H.P. Diagnostic CT scans: institutional informed consent guidelines and practices at academic medical centers. AJR Am J Roentgenol 187 (2006) 282-287
25. Lee C.I., Haims A.H., Monico E.P., Brink J.A., and Forman H.P. Diagnostic CT scans: assessment of patient, physician, and radiologist awareness of radiation dose and possible risks. Radiology 231 (2004) 393-398
26. Reddan D., and Fishman E.K. Radiologists' knowledge and perceptions of the impact of contrast-induced nephropathy and its risk factors when performing computed tomography examinations: a survey of European radiologists. Eur J Radiol (2007)
27. Martin D.R., and Semelka R.C. Health effects of ionising radiation from diagnostic CT. Lancet 367 (2006) 1712-1714
28. Thomsen H.S. Imaging patients with chronic kidney disease: CIN or NSF?. Radiol Med (Torino) 112 (2007) 621-625
29. Dangas G., Iakovou I., Nikolsky E., et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 95 (2005) 13-19
30. Levy E.M., Viscoli C.M., and Horwitz R.I. The effect of acute renal failure on mortality. A cohort analysis. Jama 275 (1996) 1489-1494
31. McCullough P.A., Adam A., Becker C.R., et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 98 (2006) 5K-13K
32. Sandstede J.J., Roth A., Machann W., Kaupert C., and Hahn D. Evaluation of the nephrotoxicity of iodixanol in patients with predisposing factors to contrast medium induced nephropathy referred for contrast enhanced computed tomography. Eur J Radiol 63 (2007) 120-123
33. Polena S., Yang S., Alam R., et al. Nephropathy in critically Ill patients without preexisting renal disease. Proc West Pharmacol Soc 48 (2005) 134-135
34. Nyman U., Almen T., Aspelin P., Hellstrom M., Kristiansson M., and Sterner G. Contrast-medium-Induced nephropathy correlated to the ratio between dose in gram iodine and estimated GFR in ml/min. Acta Radiol 46 (2005) 830-842